Thus, by delivering isoform-selective Hsp90β and Grp94 inhibitors by a systemic and translationally relevant route, we could enhance opioid pain relief by a similar 2–threefold while rescuing tolerance and not altering morphine-induced respiratory depression. This evidence concerns the gene HSP90B1 and respiratory depression.